Last reviewed · How we verify
GGTA1 KO Thymokidney
At a glance
| Generic name | GGTA1 KO Thymokidney |
|---|---|
| Sponsor | United Therapeutics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GGTA1 KO Thymokidney CI brief — competitive landscape report
- GGTA1 KO Thymokidney updates RSS · CI watch RSS
- United Therapeutics portfolio CI